The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort
Open accessAbstract
Background Risk prediction models that incorporate biomarkers and clinicopathologic variables may be used to improve decision-making post radical prostatectomy (RP). We compared two previously validated post-RP classifiers—the Cancer of the Prostate Risk Assessment post-Surgical (CAPRA-S) and the Decipher genomic classifier (GC)—to predict prostate cancer-specific mortality (CSM) in a contemporary cohort of RP patients. Objective To evaluate the combined prognostic ability of CAPRA-S and GC to predict CSM. Design, Setting and Participants A cohort of 1,010 patients at high risk of recurrence post-RP was treated at Mayo Clinic between 2000–06. High-risk was defined by any of: pre-operative PSA >20ng/mL, pathological Gleason score ≥8 or stage pT3b. A case-cohort random sample identified 225 patients (cases defined as patients who experienced CSM), among whom CAPRA-S and GC could be determined for 185. Outcome Measurements and Statistical Analysis The scores were evaluated individually and in combination using concordance (c)-index, decision curve analysis, re-classification, cumulative incidence, and Cox regression for prediction of CSM. Results and Limitations Among 185 men, 28 experienced CSM. The c-index for CAPRA-S and GC were 0.75 (95% CI 0.65–0.84) and 0.78 (95% CI 0.68–0.88), respectively. GC showed higher net-benefit on decision curve analysis but a score combining CAPRA-S and GC did not improve AUC after optimism-adjusted bootstrapping. In 82 patients stratified to high-risk based on CAPRA-S score ≥6, GC scores were likewise high-risk for 33, among whom 17 had CSM events. GC reclassified the remaining 49 men as low to intermediate-risk; among these men 3 CSM events were observed. In multivariable analysis, GC and CAPRA-S as continuous variables were independently prognostic of CSM, with hazard ratios of 1.81 (p<0.001, per 0.1 unit change in score) and 1.36 (p=0.05, per one unit change in score). When categorized into risk groups, the multivariable HR for high CAPRA-S scores (≥6) was 2.36 (p=0.04), and 11.26 (p<0.001) for high GC scores (≥0.6). For patients with both high GC and CAPRA-S scores, cumulative incidence of CSM was 45% at 10 years. The study is limited by its retrospective design. Conclusions Both GC and CAPRA-S were significant independent predictors of CSM. GC was shown to re-stratify many men classified as high-risk based on CAPRA-S ≥6 alone. Patients with both high GC and CAPRA-S risk scores were at markedly elevated post-RP risk for lethal prostate cancer. If validated prospectively, these findings suggest that integration of a genomic-clinical classifier may enable better identification of those post-RP patients who should be considered for more aggressive secondary therapies and clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Cited by
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Mohler, J. L., Antonarakis, E. S., Armstrong, A. J., D’Amico, A. V., Davis, B. J., Dorff, T., Eastham, J. A., Enke, C. A., Farrington, T. A., Higano, C. S., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0023 · Cited by 1,532
Tendulkar, R. D., Agrawal, S., Gao, T., Efstathiou, J. A., Pisansky, T. M., Michalski, J. M., Koontz, B. F., Hamstra, D. A., Feng, F. Y., Liauw, S. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9647 · Cited by 380
Epstein, J. I., Amin, M. B., Fine, S. W., Algaba, F., Aron, M., Baydar, D. E., Beltran, A. L., Brimo, F., Cheville, J. C., Colecchia, M., et al. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0015-ra · Cited by 280
Genomic Markers in Prostate Cancer Decision Making
Cucchiara, V., Cooperberg, M. R., Dall’Era, M., Lin, D. W., Montorsi, F., Schalken, J. A., & Evans, C. P. (2018) · European Urology · doi:10.1016/j.eururo.2017.10.036 · Cited by 269
Self-citationPrensner, J. R., Zhao, S., Erho, N., Schipper, M., Iyer, M. K., Dhanasekaran, S. M., Magi-Galluzzi, C., Mehra, R., Sahu, A., Siddiqui, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71113-1 · Cited by 264
Self-citation
Metadata
- Authors
- Cooperberg, M. R., Davicioni, E., Crisan, A., Jenkins, R. B., Ghadessi, M., & Karnes, R. J.
- Venue
- European Urology
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 67
- Issue
- 2
- Pages
- 326-333
- ISSN
- 0302-2838 (ISSN-L)
- OpenAlex
- W2039651067
- Cited by
- 194
- References
- 1
- FWCI
- 19.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. https://app.cochat.ai/papers/10.1016/j.eururo.2014.05.039
- The paper
- Cooperberg, M. R., Davicioni, E., Crisan, A., Jenkins, R. B., Ghadessi, M., & Karnes, R. J. (2015). Combined Value of Validated Clinical and Genomic Risk Stratification Tools for Predicting Prostate Cancer Mortality in a High-risk Prostatectomy Cohort. European Urology. https://doi.org/10.1016/j.eururo.2014.05.039
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.